{"id":904015,"date":"2025-11-03T08:29:29","date_gmt":"2025-11-03T13:29:29","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/kamada-to-announce-third-quarter-and-nine-months-ended-september-30-2025-financial-results-on-november-10-2025\/"},"modified":"2025-11-03T08:29:29","modified_gmt":"2025-11-03T13:29:29","slug":"kamada-to-announce-third-quarter-and-nine-months-ended-september-30-2025-financial-results-on-november-10-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/kamada-to-announce-third-quarter-and-nine-months-ended-september-30-2025-financial-results-on-november-10-2025\/","title":{"rendered":"Kamada to Announce Third Quarter and Nine Months Ended September 30, 2025 Financial Results on November 10, 2025"},"content":{"rendered":"<h2>\nCompany to Host Conference Call at 8:30am ET<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"justify\">REHOVOT, Israel and HOBOKEN, N.J., Nov.  03, 2025  (GLOBE NEWSWIRE) &#8212; Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the third quarter and nine months ended September 30, 2025, prior to the open of the U.S. financial markets on Monday, November 10, 2025.<\/p>\n<p align=\"justify\">Kamada management will host an investment community conference call on Monday, November 10, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the call by dialing 1-877-407-0792 (from within the U.S.), 1-809-406-247 (from Israel), or 1-201-689- 8263 (International) using conference I.D. 13756537. The call will be webcast live on the internet at: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=L5WzfqLiSieyr5EAUC25y4kGo1U9GdeGydBmmFz3SD0IkAgeAkOj5IAXhB7GmJGd2rNuwb7NZLmRvpEmaa9Dr9sCkN2Kbv5weY6pyrrqDVspDKlWGgAEU7YXwjcr1-qR-kA8KPwaB0ILOXc595TtzO9bl38SwaR9iM8mETInwxHqc1Qn0389SJR4pi7lJveuS7awPakwStgkyXilrwjKrX1OFYm4d9YiXGYDThsnfjk=\" rel=\"nofollow\" target=\"_blank\">https:\/\/viavid.webcasts.com\/starthere.jsp?ei=1738840&amp;tp_key=92257bc662<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About Kamada <\/strong><br \/>\n        <br \/>Kamada Ltd. (the \u201cCompany\u201d) is a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field. The Company\u2019s strategy is focused on driving profitable growth through four primary growth pillars: First, organic growth from its commercial activities, including continued investment in the commercialization and life cycle management of its proprietary products, which include six FDA-approved specialty plasma-derived products: KEDRAB\u00ae, CYTOGAM\u00ae, GLASSIA\u00ae, WINRHO SDF\u00ae, VARIZIG\u00ae and HEPAGAM B\u00ae, as well as KAMRAB\u00ae, KAMRHO (D)\u00ae and two types of equine-based anti-snake venom products, and the products in the distribution segment portfolio, mainly through the launch of several biosimilar products in Israel. Second: the Company aims to secure significant new business development, in-licensing, collaboration and\/or merger and acquisition opportunities, which are anticipated to enhance the Company\u2019s marketed products portfolio and leverage its financial strength and existing commercial infrastructure to drive long-term growth. Third: the Company is expanding its plasma collection operations to support revenue growth through the sale of normal source plasma to other plasma-derived manufacturers, and to support its increasing demand for hyper-immune plasma. The Company currently owns three operating plasma collection centers in the United States, in Beaumont Texas, Houston Texas, and San Antonio, Texas. Lastly, the Company is leveraging its manufacturing, research and development expertise to advance the development and commercialization of additional product candidates, targeting areas of significant unmet medical need, with the lead product candidate Inhaled AAT, for which the Company is continuing to progress the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial. FIMI Opportunity Funds, the leading private equity firm in Israel, is the Company\u2019s controlling shareholder, beneficially owning approximately 38% of the outstanding ordinary shares.<\/p>\n<p align=\"justify\">\n        <strong>CONTACTS:<\/strong><br \/>\n        <br \/>Chaime Orlev<br \/>Chief Financial Officer<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IZ3FRXuy_R98tZU2rn7dXUDvfktcNpsJvdO1Y3iqXoJPrn9WmJyn-ffrSK-s_GRgcBcoS7FS1qpRPT9g5_rrJw==\" rel=\"nofollow\" target=\"_blank\">IR@kamada.com<\/a><\/p>\n<p align=\"justify\">Brian Ritchie<br \/>LifeSci Advisors, LLC<br \/>212-915-2578<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9K1cn8DSJC7BNzwFOOwypoRhYNaJme9Si0BKafupyNcChMHFNumi2j3u8EYctck0x_JbhXC0QYRj5piTqvL8mB7bkqXYCXW7ectRU2KMg9Ks-OllNfLsVG79cUM-6C-x\" rel=\"nofollow\" target=\"_blank\">britchie@LifeSciAdvisors.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2Njg2MiM3MjM4NzIzIzIwMTcxNTI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NzQ0MjE0Y2YtOTg0OC00MzI4LWJiODUtOTAxMzZkZjc2NGE0LTEwMjg3MjUtMjAyNS0xMS0wMy1lbg==\/tiny\/Kamada-Ltd-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Company to Host Conference Call at 8:30am ET REHOVOT, Israel and HOBOKEN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) &#8212; Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the third quarter and nine months ended September 30, 2025, prior to the open of the U.S. financial markets on Monday, November 10, 2025. Kamada management will host an investment community conference call on Monday, November 10, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the call by dialing &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kamada-to-announce-third-quarter-and-nine-months-ended-september-30-2025-financial-results-on-november-10-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Kamada to Announce Third Quarter and Nine Months Ended September 30, 2025 Financial Results on November 10, 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-904015","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Kamada to Announce Third Quarter and Nine Months Ended September 30, 2025 Financial Results on November 10, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kamada-to-announce-third-quarter-and-nine-months-ended-september-30-2025-financial-results-on-november-10-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kamada to Announce Third Quarter and Nine Months Ended September 30, 2025 Financial Results on November 10, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Company to Host Conference Call at 8:30am ET REHOVOT, Israel and HOBOKEN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) &#8212; Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the third quarter and nine months ended September 30, 2025, prior to the open of the U.S. financial markets on Monday, November 10, 2025. Kamada management will host an investment community conference call on Monday, November 10, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the call by dialing &hellip; Continue reading &quot;Kamada to Announce Third Quarter and Nine Months Ended September 30, 2025 Financial Results on November 10, 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/kamada-to-announce-third-quarter-and-nine-months-ended-september-30-2025-financial-results-on-november-10-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-03T13:29:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2Njg2MiM3MjM4NzIzIzIwMTcxNTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kamada-to-announce-third-quarter-and-nine-months-ended-september-30-2025-financial-results-on-november-10-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kamada-to-announce-third-quarter-and-nine-months-ended-september-30-2025-financial-results-on-november-10-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Kamada to Announce Third Quarter and Nine Months Ended September 30, 2025 Financial Results on November 10, 2025\",\"datePublished\":\"2025-11-03T13:29:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kamada-to-announce-third-quarter-and-nine-months-ended-september-30-2025-financial-results-on-november-10-2025\\\/\"},\"wordCount\":481,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kamada-to-announce-third-quarter-and-nine-months-ended-september-30-2025-financial-results-on-november-10-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2Njg2MiM3MjM4NzIzIzIwMTcxNTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kamada-to-announce-third-quarter-and-nine-months-ended-september-30-2025-financial-results-on-november-10-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kamada-to-announce-third-quarter-and-nine-months-ended-september-30-2025-financial-results-on-november-10-2025\\\/\",\"name\":\"Kamada to Announce Third Quarter and Nine Months Ended September 30, 2025 Financial Results on November 10, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kamada-to-announce-third-quarter-and-nine-months-ended-september-30-2025-financial-results-on-november-10-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kamada-to-announce-third-quarter-and-nine-months-ended-september-30-2025-financial-results-on-november-10-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2Njg2MiM3MjM4NzIzIzIwMTcxNTI=\",\"datePublished\":\"2025-11-03T13:29:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kamada-to-announce-third-quarter-and-nine-months-ended-september-30-2025-financial-results-on-november-10-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kamada-to-announce-third-quarter-and-nine-months-ended-september-30-2025-financial-results-on-november-10-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kamada-to-announce-third-quarter-and-nine-months-ended-september-30-2025-financial-results-on-november-10-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2Njg2MiM3MjM4NzIzIzIwMTcxNTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2Njg2MiM3MjM4NzIzIzIwMTcxNTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kamada-to-announce-third-quarter-and-nine-months-ended-september-30-2025-financial-results-on-november-10-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kamada to Announce Third Quarter and Nine Months Ended September 30, 2025 Financial Results on November 10, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kamada to Announce Third Quarter and Nine Months Ended September 30, 2025 Financial Results on November 10, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/kamada-to-announce-third-quarter-and-nine-months-ended-september-30-2025-financial-results-on-november-10-2025\/","og_locale":"en_US","og_type":"article","og_title":"Kamada to Announce Third Quarter and Nine Months Ended September 30, 2025 Financial Results on November 10, 2025 - Market Newsdesk","og_description":"Company to Host Conference Call at 8:30am ET REHOVOT, Israel and HOBOKEN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) &#8212; Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the third quarter and nine months ended September 30, 2025, prior to the open of the U.S. financial markets on Monday, November 10, 2025. Kamada management will host an investment community conference call on Monday, November 10, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the call by dialing &hellip; Continue reading \"Kamada to Announce Third Quarter and Nine Months Ended September 30, 2025 Financial Results on November 10, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/kamada-to-announce-third-quarter-and-nine-months-ended-september-30-2025-financial-results-on-november-10-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-03T13:29:29+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2Njg2MiM3MjM4NzIzIzIwMTcxNTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kamada-to-announce-third-quarter-and-nine-months-ended-september-30-2025-financial-results-on-november-10-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kamada-to-announce-third-quarter-and-nine-months-ended-september-30-2025-financial-results-on-november-10-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Kamada to Announce Third Quarter and Nine Months Ended September 30, 2025 Financial Results on November 10, 2025","datePublished":"2025-11-03T13:29:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kamada-to-announce-third-quarter-and-nine-months-ended-september-30-2025-financial-results-on-november-10-2025\/"},"wordCount":481,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kamada-to-announce-third-quarter-and-nine-months-ended-september-30-2025-financial-results-on-november-10-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2Njg2MiM3MjM4NzIzIzIwMTcxNTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kamada-to-announce-third-quarter-and-nine-months-ended-september-30-2025-financial-results-on-november-10-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/kamada-to-announce-third-quarter-and-nine-months-ended-september-30-2025-financial-results-on-november-10-2025\/","name":"Kamada to Announce Third Quarter and Nine Months Ended September 30, 2025 Financial Results on November 10, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kamada-to-announce-third-quarter-and-nine-months-ended-september-30-2025-financial-results-on-november-10-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kamada-to-announce-third-quarter-and-nine-months-ended-september-30-2025-financial-results-on-november-10-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2Njg2MiM3MjM4NzIzIzIwMTcxNTI=","datePublished":"2025-11-03T13:29:29+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kamada-to-announce-third-quarter-and-nine-months-ended-september-30-2025-financial-results-on-november-10-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/kamada-to-announce-third-quarter-and-nine-months-ended-september-30-2025-financial-results-on-november-10-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kamada-to-announce-third-quarter-and-nine-months-ended-september-30-2025-financial-results-on-november-10-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2Njg2MiM3MjM4NzIzIzIwMTcxNTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2Njg2MiM3MjM4NzIzIzIwMTcxNTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kamada-to-announce-third-quarter-and-nine-months-ended-september-30-2025-financial-results-on-november-10-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Kamada to Announce Third Quarter and Nine Months Ended September 30, 2025 Financial Results on November 10, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/904015","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=904015"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/904015\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=904015"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=904015"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=904015"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}